Towards isozyme-selective HDAC inhibitors for interrogating disease

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Histone deacetylase (HDAC) enzymes are key targets for treating various human diseases, including cancers and inflammatory conditions.
• Current HDAC inhibitors often exhibit broad-spectrum activity, leading to cytotoxic side effects and limiting therapeutic applications.
• A lack of isoform-selective inhibitors hinders the precise targeting of specific HDAC enzymes.

Purpose of the Study:

• To review advancements in the design and discovery of HDAC inhibitors with selectivity for specific classical HDAC isozymes.
• To identify opportunities for utilizing isozyme-selective HDAC inhibitors as chemical probes.
• To investigate the biological roles of individual HDAC enzymes in disease pathogenesis.

Main Methods:

• Literature review of recent studies on HDAC inhibitor design and discovery.
• Analysis of strategies for achieving isozyme selectivity among the eleven classical HDACs.
• Discussion of the application of selective inhibitors as research tools.

Main Results:

• Progress has been made in developing HDAC inhibitors with improved selectivity for certain HDAC isozymes.
• Selective inhibitors offer potential for targeted therapies with reduced side effects compared to broad-spectrum agents.
• Isozyme-selective HDAC inhibitors can serve as valuable chemical probes to elucidate enzyme functions.

Conclusions:

• The development of selective HDAC inhibitors is advancing, offering new therapeutic avenues.
• Targeted inhibition of specific HDAC isozymes holds promise for more effective disease treatment.
• Selective HDAC inhibitors are essential tools for understanding HDAC biology in health and disease.